Articles tagged "Pharmacokinetics"

2020 American Transplant Congress
The Effects of Rivaroxaban and Apixaban on Tacrolimus Pharmacokinetics
A. C. Scheibner¹, C. Franco-Martinez¹, E. Kincaide¹, R. Hall¹, C. Long²
¹Pharmacotherapy Division, College of Pharmacy, The University of Texas at Austin, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Feik School of Pharmacy, University of the Incarnate Word, University Health System, The University of Texas Health Science Center at San Antonio, San Antonio, TX
*Purpose: To clarify the pharmacokinetic impact of rivaroxaban (RIVA) and apixaban (APIX) on tacrolimus (TAC) concentrations.*Methods: Solid organ transplant recipients 18-years or older who were…
2020 American Transplant Congress
Belatacept Removal by Plasmapheresis: Kinetics, Dose Adjustments and Clinical Recommendations
S. Tremblay¹, N. Wilson¹, B. Miyagawa², H. Kuzaro¹, A. R. Shields³, R. R. Alloway¹, A. Govil¹, J. Kremer⁴, E. Woodle¹, T. Mizuno², A. A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's, Cincinnati, OH, ³U Cincinnati / Christ Hospital, Cincinnati, OH, ⁴Christ Hospital, Cincinnati, OH
*Purpose: Belatacept (BELA), a protein immunosuppressant, has limited available pharmacokinetic (PK) data. Available PK data, limited to product development analyses, shows moderate intrapatient variability with…
2020 American Transplant Congress
Largest Experience of Safety, and Efficacy of Patiromer in Solid Organ Transplants (SOT)
P. Singh¹, H. Winters², T. E. Pesavento¹, K. Schnelle²
¹Transplant Nephrology, Ohio State University, Columbus, OH, ²Transplant Pharmacy, Ohio State University, Columbus, OH
*Purpose: Hyperkalemia, a potentially life‐threatening electrolyte abnormality, is commonly seen SOT. The predisposing factors are renal-dysfunction, and medications (CNI, TMP-SMX, ACEI, and ARBs). Patiromer, a…
2020 American Transplant Congress
Lack of Drug-Drug Interaction between Maribavir and Voriconazole
I. H. Song¹, K. Ilic², J. Wu³
¹Quantitative Clinical Pharmacology, Shire, a Takeda Company, Lexington, MA, ²Rare Disease TAU, Shire, a Takeda Company, Lexington, MA, ³Biostat, Shire, a Takeda Company, Lexington, MA
*Purpose: Maribavir is being evaluated in Phase 3 trials for the treatment of cytomegalovirus infections in transplant recipients. These patients often take numerous concomitant medications,…
2020 American Transplant Congress
Evaluation of Optimization of Workflow for Timing of Inpatient Therapeutic Drug Monitoring of Maintenance Immunosuppressive Drugs in Abdominal Transplant Recipients
J. Schulte, S. Mehta, E. Vargas, K. Cunningham
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Therapeutic drug monitoring (TDM) is essential to the safety and efficacy of immunosuppressants (IS) given their narrow therapeutic index. After an internal review, it…
2020 American Transplant Congress
Relationship between Tacrolimus Intrapatient Variability and Medication Adherence in Kidney Transplant Recipients
A. D. Leino, K. Abuls, J. L. Rodgers, K. Kuntz
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Intrapatient variability (IPV) has been established as a risk factor for poor post-transplant outcomes. IPV is frequently proposed to be related to nonadherence but…
2020 American Transplant Congress
Basiliximab Induction in the Obese: One Size Does Fit All
A. D. Reticker¹, D. Choi¹, A. B. Lichvar¹, C. Kane², I. Tzvetanov³, E. Benedetti³, J. J. Benken¹
¹Pharmacy Practice, University of Illinois Hospital and Health Sciences System, Chicago, IL, ²Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ³Surgery, University of Illinois Hospital and Health Sciences System, Chicago, IL
*Purpose: Surgical advancements allow more obese (BMI> 30 kg/m2) patients to receive a renal transplant. The original clinical and pharmacokinetic (PK) trials in transplantation immunosuppression…
2020 American Transplant Congress
Enough Initial Tacrolimus Blood Concentration is Crucial Even with Additional Everolimus in Corticosteroid Early Withdrawal Regimen for Kidney Transplant Recipients
H. Sasaki¹, T. Tanabe¹, H. Higuchi¹, T. Tsujimoto², H. Harada¹
¹Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan, ²Pharmacy, Sapporo City General Hospital, Sapporo, Japan
*Purpose: Everolimus (EVR) in combination with low-dose calcineurin inhibitor has been demonstrated in clinical trials to have comparable efficacy in low immunological risk kidney transplant…
2020 American Transplant Congress
Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
I. H. Song¹, K. Ilic², J. Wu³
¹Quantitative Clinical Pharmacology, Shire, a Takeda Company, Lexington, MA, ²Rare Disease TAU, Shire, a Takeda Company, Lexington, MA, ³Biostat, Shire, a Takeda Company, Lexington, MA
*Purpose: Maribavir, an investigational agent for cytomegalovirus (CMV) infection in transplant recipients, has received Breakthrough Therapy Designation. Maribavir is metabolized primarily in the liver through…
2019 American Transplant Congress
Mycophenolic Acid Area under the Curve Monitoring via Limited Sampling Strategy in Pediatric Heart Transplant Recipients
S. Crow, S. H. Dahl, J. N. Johnson
Mayo Clinic, Rochester, MN
*Purpose: The study aim was to investigate exposure to mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), after pediatric orthotopic heart transplantation (pOHT).…